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ABSTRACT

The maintenance of cellular levels of free fatty acids and acyl-CoAs, the activated form of
free fatty acids, is extremely important as imbalances in lipid metabolism have serious
consequences for human health. Acyl-CoA thioesterases (ACOTs) hydrolyze acyl-CoAs to
the free fatty acid and CoASH, and thereby have the potential to regulate intracellular levels
of these compounds. We have previously identified and characterized a mouse ACOT gene
cluster, comprised of six genes that apparently arose by gene duplications, encoding acylCoA thioesterases with localizations in cytosol (ACOT1), mitochondria (ACOT2) and
peroxisomes (ACOT3-6). However, the corresponding human gene cluster contains only
three genes, ACOT1, ACOT2 and ACOT4 coding for full-length thioesterase proteins, of
which only one is peroxisomal (ACOT4). We therefore set out to characterize the human
genes, and we here show that the human ACOT4 protein catalyzes the activities of three
mouse peroxisomal ACOTs (ACOT3, 4, and 5), being active on succinyl-CoA and mediumto long-chain acyl-CoAs, while ACOT1 and ACOT2 carry out similar functions to the
corresponding mouse genes. These data strongly suggest that the human ACOT4 gene has
acquired the functions of three mouse genes by a functional convergent evolution that also
provides an explanation for the unexpectedly low number of human genes.

Keywords: β-oxidation, acyl-CoA, peroxisome, fatty acids.
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INTRODUCTION
Imbalances in fatty acid metabolism have serious consequences for human health and the
onset and progression of several chronic diseases, such as coronary artery disease and
atherosclerosis, dyslipidemia, obesity and diabetes. The central role of free fatty acids and
acyl-CoAs (the activated form of fatty acids) is evident by the numerous intracellular
processes in which these molecules are key components. These processes (reviewed in (1))
include oxidation of fatty acids (αβ and ω-oxidation), biosynthesis of lipids, and allosteric
regulation of a number of enzymes (2-4) and opening of KATP-channels in human pancreatic
beta-cells (5). There are, however, many processes that are activated by acyl-CoAs and
inhibited by the free fatty acids or vice versa, showing the importance of maintaining the
balance of these compounds in-vivo. It has recently been shown that palmitoyl-CoA inhibits
AMP-activated protein kinase (AMPK) indirectly, by a specific and concentration dependent
inactivation of its-upstream kinase (6). Another example where the balance of free fatty acids
versus acyl-CoAs is important, is in the activation of the peroxisome proliferator-activated
receptors (PPARs) by free fatty acids (7-10) and more recently also by CoA esters of longchain fatty acids (acyl-CoAs) (11). A recently recognized way in which the cell can control
the intracellular acyl-CoA and free fatty acid levels is via the activity of enzymes named
acyl-CoA thioesterases (ACOTs), which can hydrolyze acyl-CoAs to the corresponding free
fatty acid and coenzyme A (CoASH) (for reviews see (12, 13)). These acyl-CoA thioesterases
are expressed in several cellular compartments that coincide with metabolic processes
involving acyl-CoAs.

In 1995, a particular family of acyl-CoA thioesterases was identified in rat and was named
Type-I acyl-CoA thioesterases (14). In the past few years, the cloning of cDNAs and genes
have identified the Type-I acyl-CoA thioesterases to be a novel gene family with six
members in mouse, a cytosolic isoform (Acot1, previously CTE-I), a mitochondrial isoform
(Acot2, previously MTE-I), and four peroxisomal isoforms (Acot 3, 4, 5 and 6, previously
PTE-Ia, -Ib, -Ic, and –Id) (15-17). Both the sequence similarity and the gene organization
show a very high degree of conservation, suggesting that these genes have evolved by gene
duplications. The identification of four peroxisomal ACOTs was surprising, but the
characterization of their acyl-CoA substrate specificities showed that they catalyze distinct
activities, and also show individual tissue expression. However, based on the multiple and
important functions that peroxisomes play in degradation of a variety of lipids, which is
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reflected in the severity of peroxisomal disorders (for reviews, (18, 19)), it is tempting to
speculate that these ACOTs participate in regulation of β-oxidation and release of βoxidation products. In mouse, this Type-I gene cluster is located on mouse chromosome 12
D3 within 120 kb of DNA. We have now characterized the genes in the corresponding gene
cluster of Type-I ACOTs in human, which is localized on human chromosome 14q24.3.
However, this cluster contains four genes of which three genes are transcribed to encode fulllength ACOTs and only one gene encodes a peroxisomal acyl-CoA thioesterase (ACOT4).
We here show that the human ACOT4 gene apparently has evolved into a multifunctional
protein that catalyzes the combined activities of mouse ACOT3, 4 and 5, while human
ACOT1 and ACOT2 have similar functions to the mouse orthologs.

MATERIALS AND METHODS

Cloning and expression of acyl-CoA thioesterases
Oligonucleotides were designed based on the sequence of the ORFs for human ACOT1,
ACOT2, and ACOT4. Due to the very high sequence identity between ACOT1 and ACOT2
it was not possible to PCR amplify individual transcripts of ACOT1 and ACOT2. We
obtained the ACOT2 ORF using PCR amplification from human liver and purchased a clone
containing the cDNA for ACOT1, Accession No. BM543491, (Image clone No. 5726581,
UK HMGP Resource centre, Hinxton, UK) and used this as a template for PCR amplification
of ACOT1. ACOT1 and ACOT2 were cloned into pET16b (Novagen Inc., Darmstadt,
Germany) using the following primers: 5’-CATATGTCACTTTTGATGGGATTGTC-3’ and
5’-CATATGGCGGCGACGCTGAT-3’ with NdeI sites indicated in bold. The ACOT4 was
cloned into the pET102 (Invitrogen Corp., California, USA), in frame with thioredoxin. The
5’ primer sequence was 5’-CACCATGTCAGCAACGCTGATCCTG-3’ and was constructed
to contain an overhang of CACC for cloning into pET102. The 3’ primer sequence was 5’CAATTTAGGGACAGCTGTTTTCTG-3’. The ORF for ACOT4 was amplified by RT-PCR
from human liver total RNA. RT-PCR was performed in a Perkin-Elmer 2600 using the One
Step RT-PCR kit (Takara Biomedicals, Shiga, Japan). Thermal cycling was performed at
50oC for 30 min and 94oC for 2 min, followed by 35 cycles of 94oC for 30 sec, 51.5oC for 30
sec (ACOT2) or 60oC for 30 sec (ACOT4) and 72oC for 3 min. The resultant PCR products
were cloned into pET102 or pET16b respectively and sequenced (Cybergene AB, Huddinge,
Sweden).
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The plasmids containing the human ACOT1, 2 and 4 were then used to transform
BL21(DES3)pLysS cells (Novagen Inc., Darmstadt, Germany). Bacteria were cultured in 500
ml Luria-Bertani medium at 37oC with addition of ampicillin (50 µg/ml) and
chloramphenicol (34 µg/ml) until the OD600nm was approximately 0.6. Protein expression was
induced by addition of 1 mM isopropyl-1-thio-β-D-galactopyranoside and cells were grown
for 3 hours at 37oC (ACOT1 and ACOT2) or at 30 oC for 5 h (ACOT4). The recombinant
proteins were purified as described previously and eluted using 500 mM imidazole (20). The
purity of the expressed proteins was examined using SDS/PAGE analysis and Coomassie
Brilliant blue staining and these purified proteins were used to measure acyl-CoA
thioesterase activity. Mouse ACOT3, 4 and 5 recombinant proteins were produced as
outlined in (16, 17) and activity measured with various acyl-CoA substrates.

Northern blot analysis
Human Multiple Tissue blots were purchased from Clontech Inc (Palo Alto, California,
USA), and analysis was carried out according to the Manufacturers instructions, using α-32Plabeled cDNA probes. The cDNA probes for the human ACOTs were constructed using RTPCR from human liver total RNA. For ACOT1 and ACOT2, a cDNA probe was amplified
corresponding to amino acids 167-371 of the open reading frame (ORF) (shown in Fig. 2).
The ACOT4 cDNA probe was amplified corresponding to amino acids 215 to 405 of the
ORF and a specific probe located in the mitochondrial targeting signal of ACOT2 was
amplified corresponding to amino acids 21 to 59 of the ORF.

Enzyme activity measurements
ACOT activity was measured spectrophotometrically at 412 nm with 5,5’-dithiobis(2nitrobenzoic acid) (DTNB). The medium contained 200 mM potassium chloride, 10 mM
HEPES and 0.05 mM DTNB (pH 7.4). An E412=13,600 M-1cm-1 was used to calculate the
activity. The acyl-CoA substrates used were obtained from Sigma-Aldrich Inc. (St. Louis,
USA). The addition of bovine serum albumin (BSA) to prevent substrate inhibition with CoA
esters was titrated for long-chain acyl-CoAs (C16-C20-CoA). A BSA:C18-CoA molar ratio
of 1.8:1 was used in measuring ACOT1 and ACOT2 activities. Otherwise addition of BSA
was not required for measurement of acyl-CoA thioesterase activity.
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Cellular localization of human ACOTs using green fluorescent fusion protein
The ORFs for the human ACOT1, 2, 4 and 6 were cloned as fusion proteins with green
fluorescent protein (GFP) to examine the intracellular localization of the proteins. ACOT6
was

amplified

using

primers

5’-ATGCTGCAGCATCCAAAGGTG-3’

and

5’-

TCTGTCAAGCACAGCAAAATATAA-3’. The ORFs were amplified using PCR and the
PCR products for ACOT1, ACOT4 and ACOT6 were cloned into the pcDNA3.1/NT-GFP
vector (Invitrogen Corp., California, USA), in-frame with the GFP, leaving the
carboxyterminal end accessible. The ACOT2 was cloned in-frame with the pcDNA3.1/CTGFP (Invitrogen Corp., California, USA), leaving the N-terminal end accessible. Sequence
analysis was performed using Big Dye Terminator Ready Reaction kit (Perkin Elmer Inc.,
Wellesley, MA, USA) and was sequenced by Cybergene AB (Huddinge, Sweden).

Human skin fibroblasts or HepG2 cells were grown in Eagles MEM (Sigma-Aldrich Inc., St.
Louis, USA), supplemented with 10% fetal calf serum (Invitrogen Corp., California, USA)
and 100 U penicillin/100 µg streptomycin in an atmosphere of 5% CO2. Cells were grown
overnight in 60 mm dishes on glass coverslips and were transfected with 10 µg of the various
plasmids using Calcium Phosphate method as described previously (20). The localization of
ACOT1, ACOT4 and ACOT6 was investigated in fibroblasts, and in the case of ACOT4,
skin fibroblasts from a Zellweger patient were also used. The localization of ACOT2 was
investigated in HepG2 cells and Mitotracker® Orange CMTMRos (Invitrogen Corp.,
California, USA) was used to confirm mitochondrial structures. Transfected cells were grown
for 48 hours and fibroblasts were treated for immunofluorescence as described (20). HepG2
cells treated with 200 nM Mitotracker® Orange for 30 mins before immunofluorescence
microscopy was carried out as previously described (20), but without use of the Tritc-labeled
antibody.

RESULTS
Identification of a human ACOT gene cluster
Previous data had identified six mouse Acot genes in a cluster which are located within 120
kb on mouse chromosome 12 D3 (15-17). Database searches using the cDNA sequences for
the mouse Type-I Acot genes identified four putative human ACOT genes on chromosome
14q24.3, located within 80 kb of genomic sequence (Fig. 1). Based on homology to the
mouse genes, we identified the putative human orthologs of Acot1, Acot2, Acot4 and Acot6 in
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the human gene cluster. The distance between the genes is approximately 25.7 kb between
ACOT1 and ACOT2, 16.5 kb between ACOT2 and ACOT4 and 16.9 kb between ACOT4 and
ACOT6. Comparison of the two gene clusters reveals two striking differences, firstly that the
order of the ACOT1 and ACOT2 genes are different in the human genome compared to
mouse, and second, that the human gene cluster only contains one putative gene encoding a
peroxisomal ACOT. Similar to the mouse genes, the open reading frames for three of these
genes are coded for by three exons (ACOT1, ACOT2 and ACOT4) whereas the fourth gene
identified in the cluster, ACOT6, contained the genomic information for all 3 exons (which
would result in a full-length ACOT protein), but apparently is translated from a methionine at
the end of exon 2 through exon 3. This is based on EST sequences, the estimated size of the
transcript detected by Northern blot (data not shown), and the facts that we could not amplify
the predicted full-length open reading frame, but we could amplify a transcript that covered
part of exon 2 and exon 3.

Data base searches in the entire human genome did not indicate the presence of any other
genes that would correspond to mouse Acot3 or Acot5, but a further gene was identified on
chromosome 19q13.12 that shows 91% sequence identity at nucleotide level to the ACOT4
gene on chromosome 14. However, this gene on chromosome 19 lacks introns and contains
several stop codons, which will not result in active protein. Interestingly, searches in EST
databases show that the pseudogene is expressed in purified pancreatic islets (EST No.
CA843741, CB177282 and CA843493), brain (EST No. BI827748 and AW090080), and
placenta (EST No. DB328688 and DA849162).

Alignment of the deduced amino acid sequences for the open reading frames of the ACOT1,
ACOT2 and ACOT4 genes shows the striking conservation between the various ACOTs (Fig.
2). The ACOT1 and ACOT4 genes encode proteins of 421 amino acids, with the latter
containing -PKL at its carboxyterminal, which is a variant of the peroxisomal type-1
targeting signal (PTS1) that can target proteins to peroxisomes (21). ACOT2 encodes a
protein of 483 amino acids and contains a 62 amino acid leader sequence at the N-terminal,
which targets the protein to mitochondria (see below). The 421 amino acids of ACOT2 that
align to ACOT1 show 98.6% sequence identity, with only 5 amino acids being different. The
three amino acids identified to be the catalytic triad of the active site in the mouse ACOT
enzymes (22), a serine (acting as the nucleophile) in a Gly-X-Ser-X-Gly motif common to
serine esterases, a histidine and an aspartic acid are all conserved in the human enzymes
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(indicated in Fig. 2). The serine is located at position 232 of ACOT1, the aspartic acid at 326
and the histidine at 360.

Subcellular localization of the human ACOTs
The subcellular localization of the four human ACOTs identified in this study was examined
by expression of the ACOTs in human skin fibroblasts and HepG2 cells as GFP fusion
proteins. The rationale for choosing either N-terminal or C-terminal GFP was based on the
presence of putative targeting signals at the N- or C-terminal ends, and also on previous data
obtained for localization of the mouse orthologs. The ACOT1 (homologous to the mouse
ACOT1 which is cytosolic (23)) contains no apparent targeting signal but contains a PTS1like sequence of –SKV at its C-terminal end. However transfection of this GFP fusion protein
into human fibroblasts resulted in a protein with a diffuse pattern of expression with no
visible punctate staining, in line with a cytosolic localization (Fig. 3A). ACOT6 also contains
a PTS1-like sequence of –SKI at its C-terminal end but this GFP fusion protein was also
localized in cytosol (Fig. 3B). The ACOT2 protein contains a putative mitochondrialtargeting signal at its N-terminal end. This GFP fusion protein showed a typical pattern for
mitochondrial localization as judged by immunofluorescence microscopy (Fig. 3C). Use of a
mitotracker confirmed that the ACOT2 fusion protein was localized in mitochondria (Fig.
3D). The human ACOT4 contains a near-consensus PTS1 of -PKL at its C-terminal, which is
also present in C. tropicalis sterol carrier protein (POX18), and has been shown to target
proteins to peroxisomes (24). We transfected the ACOT4/NT-GFP vector into both control
fibroblasts and fibroblasts from a Zellweger patient, which are unable to import peroxisomal
matrix proteins. Using immunofluorescence microscopy for GFP detection, ACOT4 showed
a punctate pattern of expression in control fibroblasts, indicative of a peroxisomal
localization (Fig. 3E). However, in Zellweger fibroblasts, transfection of ACOT4 resulted in
a diffuse GFP expression, showing an inability of the protein to be imported into peroxisomes
(Fig. 3F).

Recombinant expression and characterization of human and mouse ACOT proteins
The cloning of the open reading frames of ACOT1 and ACOT2 into pET16b and ACOT4 into
pET102 vectors resulted in expression of these proteins as His-tagged fusion proteins, to
allow for purification using affinity chromatography. Following purification on a HiTrap™
column, the purified ACOT1 and ACOT2 were detected as single bands of approximately 46
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kDa in mass on SDS/PAGE gel stained with Coomassie Brilliant blue, whereas ACOT4 was
detected as an approximately 60 kDa band as a thioredoxin fusion protein (data not shown).

The human ACOT4 gene shows strongest similarity to ACOT4 in mouse, and is therefore
likely to be the human ortholog of mouse ACOT4. The mouse ACOT4 enzyme was recently
shown to be a highly specific succinyl-CoA thioesterase, with only low activity with glutarylCoA and no activity with any other tested acyl-CoAs (17). In line with this, characterization
of recombinant human ACOT4 indeed showed highest activity with succinyl-CoA (V max≈581
nmol/min/mg protein, and Km≈14 µM), with much lower Vmax and higher Km with glutarylCoA (132 nmol/min/mg protein and 147 µM, respectively). Surprisingly, ACOT4 was also
active on all long-chain saturated acyl-CoAs of >8 carbon atoms as well as all tested
unsaturated acyl-CoAs (C18:1, C18:2 and C20:4). The calculated Vmax and Km values of
ACOT4 with C14-CoA (which was the best long-chain acyl-CoA substrate) were 137
nmol/min/mg protein and 3.4 µM, respectively. Fig. 4A summarizes the activity of human
ACOT4 with all acyl-CoAs tested, demonstrating that human ACOT4 is a succinyl-CoA
thioesterase that also hydrolyzes long-chain saturated and unsaturated monocarboxylic acylCoAs. The pattern of activity of human ACOT4 mirrors the combined activities of the
recently characterized mouse ACOT3, ACOT4 and ACOT5 proteins (summarized in Fig.
4B). Therefore the human peroxisomal ACOT4 can replace the function of 3 distinct
peroxisomal enzymes in mouse. Interestingly, although succinyl-CoA (C4-dicarboxylylCoA) was the best substrate for ACOT4, the corresponding C4-monocarboxylyl-CoA
(butyryl-CoA) was not a substrate, and in contrast the C12 dicarboxylyl-CoA was not a
substrate in spite of the fact that the corresponding C12 monocarboxylyl-CoA was a good
substrate (data not shown). These data demonstrate that human ACOT4 has not simply
evolved into a non-specific acyl-CoA thioesterase, but rather that human ACOT4 has
acquired the combined activities of mouse ACOT3, ACOT4 and ACOT5.

Kinetic characterization of recombinant human ACOT1 and ACOT2 showed very similar
substrate specificities, with both enzymes being mainly active on long-chain saturated acylCoAs of 12 to 20 carbon atoms, and long-chain unsaturated acyl-CoAs such as C16:1-CoA,
C18:1-CoA (Fig. 5A and B). The data thus show that ACOT1 and ACOT2 function as longchain acyl-CoA thioesterases with no detectable activity with acyl-CoAs of 8 carbon atoms or
shorter. Kinetic characterization of ACOT1 and ACOT2 show that the Km for long-chain
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acyl-CoAs is in the low µM range, demonstrating that these are probably the in-vivo
substrates for the enzymes (Table I).

Tissue expression of human ACOTs
Northern blot analysis was carried out to examine the tissue expression of the various human
ACOTs (Fig. 6). As ACOT1 and ACOT2 in human show 99% sequence identity to eachother,
it was not possible to make a probe that would be specific for the ACOT1. Using a cDNA
probe to ACOT1/ACOT2, one transcript of approximately 1.8 kb was detected with highest
levels in heart, liver, muscle and kidney. However, a cDNA probe corresponding to the
mitochondrial-targeting signal of the ACOT2 was constructed, which will distinguish
between these two mRNAs. Using the ACOT2 specific probe, the mRNA signal was again
strongest in heart, liver, muscle and kidney and also weakly in placenta and pancreas,
suggesting that ACOT2 is much more strongly expressed than ACOT1. This is further
supported by searches in the EST database, which showed that ESTs corresponding to
ACOT2 were much more abundant than ESTs corresponding to ACOT1. The ACOT4 was
detected as two transcripts of approximately 1.7 and 2.2 kb, with strongest expression in liver
and kidney and weaker expression in placenta, heart and muscle. These two transcripts were
differentially expressed with the lower transcript expressed mainly in liver and kidney,
whereas the upper transcript was detectable in heart, liver, muscle and kidney.

DISCUSSION

We have previously identified and characterized a gene cluster on chromosome 12 D3 in
mouse (15-17), containing six individual genes, Acot1 (cytosolic), Acot2 (mitochondrial) and
Acot3, 4, 5 and 6 (all peroxisomal). Here we have characterized the corresponding cluster in
human, which consists of four ACOT genes on chromosome 14q24.3. Three of these genes,
ACOT1, ACOT2 and ACOT4 encode full-length ACOT proteins, and one gene, ACOT6, is
translated from a methionine at the end of exon 2 into a putative open reading frame of only
207 amino acids. Although the catalytic amino acids would be contained in the protein, it is
not clear whether the protein will be active. Interestingly the mouse ACOT6 ortholog
contains a canonical PTS-1 targeting signal of –SKL in the C-terminal end, which targets
mouse ACOT6 to peroxisomes (Westin et al, unpublished results), while human ACOT6
ends with an isoleucine instead of leucine (C-terminal end of -SKI), which results in a
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cytosolic localization. It is remarkable that mouse contains so many peroxisomal ACOT
enzymes, whereas human contains only one functional peroxisomal Type-I ACOT. However,
our finding that human ACOT4 hydrolyzes succinyl-CoA, glutaryl-CoA and long-chain acylCoAs, provides a plausible explanation for the difference in the number of peroxisomal
ACOTs in human and mouse. In mouse, there are three Type-I ACOT enzymes characterized
to date that hydrolyze straight-chain acyl-CoA esters, the ACOT3 active on long-chain acylCoAs and the ACOT5 active on medium chain acyl-CoAs (16), together with ACOT4, a
newly identified succinyl-CoA/glutaryl-CoA thioesterase (17). While mouse ACOT4 only
hydrolyzes succinyl-CoA with high activity, and glutaryl-CoA with low activity, human
ACOT4 also hydrolyzes saturated and unsaturated medium- to long-chain acyl-CoAs. It is
therefore reasonable to suggest that human ACOT4 catalyzes the combined activities of
mouse ACOT3, 4 and 5. Also, human ACOT4 is mainly expressed in liver and kidney,
similar to mouse Acot3 and 4, further strengthening a functional redundancy. It would
therefore be very interesting to compare this gene cluster in various species to trace the
appearance/disappearence of genes in this cluster, and to follow the acquisition of the
different activities in ACOT4 in higher vertebrates. A similar convergent evolution from
mouse to human is seen among acyl-CoA oxidases, peroxisomal enzymes catalyzing the first
reaction in the β-oxidation of various acyl-CoAs in peroxisomes. While rat and mouse have
three genes encoding straight-chain acyl-CoA oxidase, trihydroxycoprostanoyl-CoA oxidase
and branched-chain (pristanoyl-CoA) acyl-CoA oxidase, (25), human has only two genes
encoding the straight-chain oxidase and a combined trihydroxycoprostanoyl-CoA and
pristanoyl-CoA oxidase (26, 27). Interestingly, in human there is also an intron-less ACOT
pseudogene located on chromosome 19q13.12, which shows very high similarity to ACOT4.
Although this pseudogene is expressed at mRNA level in several tissues, the function is not
known. However, recently it was shown that a pseudogene of the Makorin 1 gene (Makorin
1-p1) could regulate the mRNA stability of its homologous coding gene (28). Therefore the
ACOT pseudogene may have a regulatory function on the expression of ACOT4. The fourth
gene in the ACOT gene cluster, ACOT6, contains the genetic information for all three coding
exons common to the ACOT genes described in this work, however, translation apparently
starts from a methionine present at the end of exon 2. We were able to amplify a PCR product
containing this truncated open reading frame of ACOT6, but it is not known whether ACOT6
is expressed as an active protein. The corresponding mouse ACOT6 gene encodes a 46 kDa
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protein that is expressed, but as yet the substrate for this enzyme has not been defined
(Westin et al, unpublished results).

Cloning and sequence analysis of ACOT1 and ACOT2 revealed open reading frames
encoding proteins of 421 amino acids that aligned to eachother, with 98.6% sequence
identity. While ACOT2 contains a further 62 amino acids in-frame at the N-terminal end that
functions as a mitochondrial targeting signal, ACOT1 lacks these amino acids. ACOT2 was
previously cloned as a human peroxisomal acyl-CoA thioesterase named PTE2 (29), however
sequence alignment of PTE2 reveals that it relates to ACOT2 without its mitochondrial
targeting signal. The assignment of the name PTE2 was based on the finding that the -SKV
tripeptide at the C-terminal end acted as a weak peroxisomal targeting signal, mediating some
import of this protein into peroxisomes. Indeed it has been shown that mutation of the
peroxisomal targeting signal from the consensus –SKL to -SKV results in mistargeting to
cytosol (30). We now show that ACOT2 contains a mitochondrial-targeting signal at its Nterminal end, which targets the protein to mitochondria. In line with the apparent lack of
targeting signals in ACOT1, the protein remained in the cytosol in the GFP experiments.

Mouse and human peroxisomes contain a further acyl-CoA thioesterase now renamed
ACOT8 (previously called PTE1, hTE, hACTEIII and PTE-2) in a new acyl-CoA
thioesterase nomenclature system (31), which can hydrolyze a wide variety of CoA esters,
including bile acid-CoAs, branched-chain-CoAs and long- medium- and short chain acylCoAs (20, 32). Therefore it appears that mouse peroxisomes contain 5 different peroxisomal
acyl-CoA thioesterases, hydrolyzing a broad spectrum of CoA esters, whereas human
contains only 2 genes coding for peroxisomal acyl-CoA thioesterases, whose activity cover
the same span of CoA ester substrates. The need for several peroxisomal ACOT enzymes
with different specificities becomes evident in view of the multiple functions that
peroxisomes play in chain-shortening of various carboxylic acids (as peroxisomes do not
catalyze complete β-oxidation of lipids), including long- and very long-chain fatty acids,
dicarboxylic acids, bile acid intermediates and xenobiotic carboxylic acids (19, 33).
Furthermore, fatty acids are apparently transported across the peroxisomal membrane as
CoA-esters (in contrast to mitochondria that utilizes a carnitine-acylcarnitine transport
system), while fatty acid degradation products may be transported out of the peroxisome as
carnitine esters, glycine or taurine conjugates or as the free acids. This implies that ACOTs
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may serve essential functions in peroxisomes to regulate β-oxidation (CoASH levels) as well
as in termination of β-oxidation at various chain-lengths for exit out of the organelle. In view
of this, we were surprised to only find one peroxisomal Type-I ACOT in the human genome.
However, the finding here that ACOT4 in fact catalyzes the activities of three mouse ACOTs
not only explains the lower number of human ACOT genes, but also underscores the
physiological importance of these ACOTs in peroxisomal lipid metabolism.

ACOTs play key roles in maintaining the intracellular ratio between the CoA esters of
various lipids and the free acid e.g. acyl-CoAs and free fatty acids. Putative functions for
these ACOT enzymes in cytosol, mitochondria and peroxisomes have been described in
detail in a recent review, mainly based on work carried out on the mouse enzymes (12).
ACOT1 and ACOT2 have very similar substrate specificities, both active on long-chain acylCoAs, which is not surprising based on their extremely high level of sequence identity
(>98%). However, these enzymes show two distinct cellular localizations in cytosol and
mitochondria and therefore have specific functions within these compartments in the
metabolism of long-chain acyl-CoAs. In mitochondria, ACOT2 has been suggested to be
involved in a co-ordinate shuttle pathway together with uncoupling protein 3 (UCP3) in
muscle and brown adipose tissue (34). This hypothesis suggests that free fatty acids are
shuttled out of the mitochondria by UCP3 when fatty acid β-oxidation predominates. These
free fatty acids would result from the hydrolysis of acyl-CoAs by ACOT2, thus releasing
CoASH for further reactions within the mitochondria during β-oxidation. The free fatty acids
transported out of the mitochondria by UCP3 would then be reactivated by acyl-CoA
synthetases to form acyl-CoAs, which could subsequently be transported back into the
mitochondria as a carnitine ester via the sequential action of carnitine palmitoyl transferase I
(CPTI) and the carnitine acylcarnitine (CAC) transporter. This shuttle mechanism would
prevent overloading of the mitochondria with acyl-CoA and trapping of CoASH, which is
vital for β-oxidation and the citric acid cycle to proceed. A role for ACOT1 has been
suggested in control of ligand supply for the PPAR family of nuclear receptors in the form of
acyl-CoAs or free fatty acids and/or channeling fatty acids toward degradation rather than
esterification (22).

In summary, the identification of a family of human acyl-CoA thioesterases with distinct
tissue expression and substrate specificities opens up avenues for further research into these
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enzymes, which may be important in regulation of numerous intracellular processes, as well
as for maintaining robustness in response to rapid changes in availability of energy
substrates. Patients with lowered ACOT activity have recently been described (35), however,
no patients deficient in the Type-I family of ACOT enzymes characterized in this study have
yet been identified. The role of ACOT enzymes in lipid metabolism within different
intracellular compartments suggests that future studies may reveal their importance in inborn
errors of metabolism and lipid metabolism.
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FIGURE LEGENDS

Fig. 1. Organization of the human and mouse ACOT gene clusters. Analysis of human
genomic DNA sequences was carried out as described in ‘Materials and Methods’. The
localization of the four ACOT genes is shown on chromosome 14q24.3. The open reading
frames for ACOT1, ACOT2 and ACOT4 are encoded for by three exons, whereas ACOT6 is
encoded from a methionine at the end of exon 2. The ACOT gene cluster in mouse consists
of six genes, Acot1-6. Note the different order of the Acot1 and Acot2 genes in mouse
compared to human, and that the cellular localization for each gene product is indicated. The
open square on mouse and human ACOT2 indicate the presence of N-terminal mitochondrial
targeting signals.

Fig. 2. Sequence alignment of human ACOTs. Alignment of human ACOT1, ACOT2 and
ACOT4 was performed using Clustal X. The individual exon boundaries for the ACOTs are
indicated. ACOT2 contains a 62 amino acid mitochondrial targeting signal at its N-terminal
end. The active site serine, conserved in a Gly-X-Ser-X-Gly motif, the histidine, and the
aspartic acid residues of the catalytic triad are all indicated with black arrowheads.

Fig. 3. Intracellular localization of human ACOTs. Human skin fibroblasts were
transfected with plasmids that expressed GFP fusion proteins of ACOT1, ACOT4 and
ACOT6 and HepG2 cells were tranfected with a GFP fusion protein plasmid of ACOT2.
Cells were fixed and processed for immunofluorescence microscopy. The distribution of
ACOT1 and ACOT6 was examined in control fibroblasts using a Tritc-labelled anti-GFP
antibody. ACOT2 localization was examined in HepG2 cells and Mitotracker® Orange
CMTMRos was used to confirm mitochondrial structures. (A) ACOT1, (B) ACOT6 (C)
ACOT2, (D) Mitotracker CMTMRos. The distribution of ACOT4 was investigated in
fibroblasts from a control subject (E) and in fibroblasts from a Zellweger patient (F).

Fig. 4. Human ACOT4 catalyzes the combined activities of mouse ACOT3, ACOT4 and
ACOT5. (A) Expression of recombinant human ACOT4 in pET102 was induced as
described in ‘Materials and Methods’. The substrate specificity for purified human ACOT4
was examined with various CoA esters and measured at 25 µM. (B) The figure shows the
specific activities of mouse ACOT3, ACOT4 and ACOT5 on various acyl-CoAs measured at

19
25 µM substrate concentration. Note that the activities of the monocarboxylic acyl-CoAs of
ACOT3 and ACOT5 are shown in stack columns. Dicarboxylic acids; C4, succinyl-CoA; C5,
glutaryl-CoA.

Fig. 5. Acyl-CoA substrate specificities of human ACOT1 and ACOT2. Human ACOT1
and ACOT2 were expressed in BL21(DES3)pLysS cells and purified as described in
‘Materials and Methods’. The purified recombinant proteins were used to measure
thioesterase activity with various acyl-CoAs at 15 µM. (A) ACOT1 (B) ACOT2.
BSA:acyl-CoA in a molar ratio of 1.8:1 was used in measuring C18-CoA thioesterase
activity.

Fig. 6. Tissue expression of human ACOTs. Northern blot analysis was carried out on a
Human Multiple Tissue Blots using α-32P-labeled cDNA probes for ACOT1, ACOT2 and
ACOT4 as described in ‘Materials and Methods’.
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Table I. Recombinant human ACOT1 and ACOT2 were purified and characterized for acylCoA thioesterase activity with various acyl-CoAs. Km and Vmax values were calculated using
the Sigma Plot or GraphPad Prism 4 enzyme kinetics programs. Km and Vmax values were
determined for saturated acyl-CoAs on two different protein preparations, and data are shown
as mean±range of two experiments. Activity was measured on unsaturated acyl-CoAs using
one protein preparation.

ACOT 1

ACOT2

Km

Vmax

Km

Vmax

(µM)

(nmol/min/mg)

(µM)

(nmol/min/mg)

C10

35.8±5.2

224±50

40.3±0.7

212±26

C12

3.6±1.0

700±152

8.9±0.2

681±94

C14

2.8±0.2

912±199

1.6±0.0

766±155

C16

3.6±2.6

691±42

2.0±0.6

656±3

C18

2.4±0.6

597±145

2.8±1.6

488±122

C20

2.0±0.2

520±41

4.8±2.0

408±64

C16:1

2.4

577

4.5

661

C18:1

4.1

258

6.1

304

C18:1 trans

2.1

309

4.3

418

Acyl-CoA
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ACOT1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
ACOT2 M S N K L L S P H P H S V V L R S E F K M A S S P A V L R A S R L Y Q W S L K S S A Q F L G S P Q L R Q V G Q I I 57
ACOT4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
ACOT1 - - - - - M A A T L I L E P A G R C C W D E P V R I A V R G L A P E Q P V T L R A S L R D E K G A L F Q A H A R Y 52
ACOT2 R V P A R M A A T L I L E P A G R C C W D E P V R I A V R G L A P E Q P V T L R A S L R D E K G A L F Q A H A R Y 114
ACOT4 - - - - - M S A T L I L E P P G R C C W N E P V R I A V R G L A P E Q R V T L R A S L R D E K G A L F R A H A R Y 52
ACOT1 R A D T L G E L D L E R A P A L G G S F A G L E P M G L L W A L E P E K P L V R L V K R D V R T P L A V E L E V L 109
ACOT2 R A D T L G E L D L E R A P A L G G S F A G L E P M G L L W A L E P E K P L V R L V K R D V R T P L A V V L E V L 171
ACOT4 C A D A R G E L D L E R A P A L G G S F A G L E P M G L L W A L E P E K P F W R F L K R D V Q I P F V V E L E V L 109

Exon 1

Exon 2

ACOT1 D G H D P D P G R L L C R V R H E R Y F L P P G V R R E P V R A G R V R G T L F L P P E P G P F P G I V D M F G T 166
ACOT2 D G H D P D P G R L L C Q T R H E R Y F L P P G V R R E P V R V G R V R G T L F L P P E P G P F P G I V D M F G T 228
ACOT4 D G H D P E P G R L L C Q A Q H E R H F L P P G V R R Q S V R A G R V R A T L F L P P G P G P F P G I I D I F G I 166

Exon 2

Exon 3

ACOT1 G G G L L E Y R A S L L A G K G F A V M A L A Y Y N Y E D L P K T M E T L H L E Y F E E A V N Y L L S H P E V K G 223
ACOT2 G G G L L E Y R A S L L A G K G F A V M A L A Y Y N Y E D L P K T M E T L H L E Y F E E A M N Y L L S H P E V K G 285
ACOT4 G G G L L E Y R A S L L A G H G F A T L A L A Y Y N F E D L P N N M D N I S L E Y F E E A V C Y M L Q H P Q V K G 223
ACOT1 P G V G L L G I S K G G E L C L S M A S F L K G I T A A V V I N G S V A N V G G T L R Y K G E T L P P V G V N R N 280
ACOT2 P G V G L L G I S K G G E L C L S M A S F L K G I T A A V V I N G S V A N V G G T L R Y K G E T L P P V G V N R N 342
ACOT4 P G I G L L G I S L G A D I C L S M A S F L K N V S A T V S I N G S G I S G N T A I N Y K H S S I P P L G Y D L R 280
ACOT1 R I K V T K D G Y A D I V D V L N S P L E G P D Q K S F I P V E R A E S T F L F L V G Q D D H N W K S E F Y A N E 337
ACOT2 R I K V T K D G Y A D I V D V L N S P L E G P D Q K S F I P V E R A E S T F L F L V G Q D D H N W K S E F Y A N E 399
ACOT4 R I K V A F S G L V D I V D I R N A L V G G Y K N P S M I P I E K A Q G P I L L I V G Q D D H N W R S E L Y A Q T 337
ACOT1 A C K R L Q A H G R R K P Q I I C Y P E T G H Y I E P P Y F P L C R A S L H A L V G S P I I W G G E P R A H A M A 394
ACOT2 A C K R L Q A H G R R K P Q I I C Y P E T G H Y I E P P Y F P L C R A S L H A L V G S P I I W G G E P R A H A M A 456
ACOT4 V S E R L Q A H G K E K P Q I I C Y P G T G H Y I E P P Y F P L C P A S L H R L L N K H V I W G G E P R A H S K A 394
ACOT1 Q V D A W K Q L Q T F F H K H L G G H E G T I P S K V
ACOT2 Q V D A W K Q L Q T F F H K H L G G H E G T I P S K V
ACOT4 Q E D A W K Q I L A F F C K H L G G T Q K T A V P K L

421
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421
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